Jandel T. Allen-Davis
Vice President, Government, External Relations and Research, Kaiser Permanente Colorado, Denver
Jandel T. Allen-Davis
Jandel Allen-Davis, MD, is vice president of Government, External Relations and Research for Kaiser Permanente Colorado. She leads the organization’s government relations and regulatory affairs, community relations and community benefit investment, clinical research activities, stakeholder engagement, communications, and advertising and marketing functions.
Dr. Allen-Davis is board certified in obstetrics and gynecology and after 25 years, transitioned from a physician leader to Kaiser Permanente’s Health Plan Leadership team. Her past roles at Kaiser Permanente included associate medical director of external relations for the Colorado Permanente Medical Group, regional director of patient safety and physician chief of the Wheat Ridge Medical Offices. Dr. Allen-Davis was elected to the Colorado Permanente Medical Group Board of Directors in 1998 and chaired the board in her final year.
A graduate of Dartmouth College and Dartmouth Medical School, Dr. Allen-Davis completed her residency at Thomas Jefferson University Hospital in Philadelphia. Before coming to work at Kaiser Permanente, she was an assistant professor of obstetrics and gynecology at the University of Colorado Health Sciences Center and spent four years in the Indian Health Service in Tuba City, Ariz., during which time she also served as member and chair of the American College of Obstetrician Gynecologists’ Committee on Alaska Native and Indian Affairs.
Dr. Allen-Davis believes health care will improve when all the primary stakeholder groups — clinicians, patients, elected officials, community leaders and employers — can collaborate effectively to put the patient at the center. “My vision is for Kaiser Permanente to be our community’s most valuable partner in health. We want to support dialogue and collaboration to help our patients, our people and Colorado thrive,” she said.
Dr. Allen-Davis is an active participant in the community, including time spent on boards for the Denver Botanic Gardens, Colorado Association of Commerce and Industry Board of Directors, Denver Metro Chamber of Commerce Board of Directors, Mile High United Way Board of Directors, Colorado Education Initiative Board of Directors, The Denver Foundation Board of Trustees and CU Foundation Board of Trustees. In 2013, she was appointed to serve on the board of Grantmakers in Health, a national organization focused on assisting funders who are actively involved in supporting nonprofits focused on community health. She is past president of the Denver Metro Chamber Leadership Foundation Board of Directors and served as the 2015 chair for the American Heart Association’s Go Red for Women Campaign.
Dr. Allen-Davis served on the Colorado State Board of Medical Examiners from 2003–2011 and served as president of the board from 2009-2011.
Dr. Allen-Davis is the proud recipient of the 2015 Colorado Black Women for Political Action, Excellence in Community Service Award, the 25 Most Powerful Women in Colorado from the Colorado Women’s Chamber in 2013, the 2013 Colorado Black Women for Political Action, Women Making History Award, the 2013 Metro Volunteers Community Impact Award, the 2012 Outstanding Women in Business in Health Care from the Denver Business Journal, and is a member of the 2012 Girl Scouts Women of Distinction inductees. She was named 2000 Kaiser Permanente Physician Volunteer of the Year and a “Top Doc” by 5280 Magazine for several years. In 2002, Dr. Allen-Davis won first place in the Professional Category of the “On My Own Time” art show from the Colorado Business Committee for the Arts.
In her spare time, Dr. Allen-Davis is a fiber artist creating original, hand-painted quilts and fiber vessels. In addition, she enjoys staying active, completing the Kaiser Permanente Colfax half-marathon in 2011.
Co-Founder & COO, Gyant, San Francisco
Stefan is an repeat entrepreneur in the digital consumer space. He started his career in strategy consulting and then led two consumer companies to successful exits in mobile gaming and e-commerce. Stefan co-founded GYANT, an artificial intelligence service that improves access to health information and care advice for millions of people. GYANT works with payors and health systems to improve patient navigation and engagement while improving effiency in provider-patient conversations.
Professor, Autonome Intelligente Systeme, Technische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg
Wolfram Burgard is Professor for Computer Science at the University of Freiburg where he heads the Laboratory for Autonomous intelligent Systems and the Cluster of Excellence BrainLinks-BrainTools. He published two books and over 300 scientific publications and is well-known for his contribution to robotics and artificial intelligence. He received the Leibniz Preis of the Deutsche Forschungsgemeinschaft and an ERC Grant of the European Research Council. He is Fellow of the AAAI, the IEEE, and the EurAI and member of the Heidelberger Akademie der Wissenschaften and Leopoldina Akademie der Wissenschaften.
Alberto Caminero Fernandez
McMaster University, Senior Postdoctoral Fellow, Hamilton, Canada
Alberto Caminero Fernandez
2003-2008: Bachelor- Biology. University of Leon (Spain) 2008-2013: PhD – Microbiology and Molecular Biology. University of Leon (Spain) 2014-2018: Postdoctoral Fellow. McMaster University (Canada)
Awards and Recognitions:
2013: Dr Schär Institute Award to the best original publication about celiac disease. Sponsor: Dr Schar Institute and Sociedad Española de Enfermedad Celiaca
2016: JA Campbell Research Young Investigator Award. Sponsor: Canadian Celiac Association.
2017: Early career investigator Award. Sponsor: The American Gastroenterology Association
Grants and Fellowships:
2008-2010: PhD Research Fellowship. Sponsor: Sacyl-Junta de Castilla y León. Spanish Regional Program for Science.
2013: European Molecular Biology Organization (EMBO) Short Fellowship. Sponsor: European Molecular Biology Organization (EMBO). Award Amount: 30,000
2014-2016. Sponsor: Canadian Institute of Health Research (CIHR) and Canadian Association of Gastroenterology (CAG). Award Amount: 90,000
2017: Farncombe-Fellowship Salary Award. Sponsor: Farncombe Family. Award Amount: 100,000.
2018: Biocodex Microbiota Foundation annual research grant. Sponsor: Biocodex. Award Amount: 40,000
Senior Vice President, Business Development, Cooley, Boston
Charlie Cameron has over 25 years of business development, investing and management consulting experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies, judges numerous business plan competitions and is a frequent speaker on innovation and entrepreneurship. He founded the Hub Angel Investment Group, which is on its fifth fund. He works with a plethora of entrepreneurs, innovators and investors in Europe, with special focus on DACH countries. Charlie is also Senior VP of Strategy at Cooley LLP, a global law firm with deep experience working with life science and tech companies and venture funds. He is on the board of the German American Business Council, Boston, the advisory board of the German Accelerator Life Science, and several other boards and advisory groups. During the past decade, Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Massachusetts.
Director of Business Development & Alliances, BiomX, Jerusalem Area
Dr. Ariel Cohen is Director of Business Development and Alliances at BiomX, a microbiome drug discovery company. Prior to his role in BiomX, Dr. Cohen co-founded two biotech companies: OnTimeBio (Diagnostics) and Ensof Biosystems (Target discovery) and managed development of three academic discoveries to drug development companies. Dr. Cohen held business development roles at Integra Holdings, Yissum (Hebrew University’s Tech Transfer Office), and Aurum Ventures MKI. Prior to that Dr. Cohen served as Senior Project Manager at Evogene (NYSE:EVGN) an agriculture biotechnology company. Dr. Cohen holds a Ph.D. in Systems Biology and an M.Sc. in Computational Biology from the Weizmann Institute of Science and has published in top peer-reviewed journals, including; Science, Nature and Cell.
Microbiome Researcher, DayTwo, Tel Aviv
PhD - Dept. of Plant Pathology & Microbiology, Faculty of Agriculture, Food & Environment, The Hebrew University, Rehovot (In collaboration with UFZ- Helmholtz Centre for Environmental Research Leipzig, Germany).
Thesis: "Deciphering predator-prey interactions in complex microbial communities"
Supervisor: Prof. Edouard Jurkevitch (Hebrew University of Jerusalem)
M.Sc - Dept. of Molecular Microbiology & Biotechnology, Tel-Aviv University (In collaboration with the Australian Institute of Marine Science, Townsville).
Thesis: "Phage Therpay of Coral Disease in the Great Barrier Reef,Australia"
Supervisors: Prof. Eugene Rosenberg (Tel-Aviv Univeristy), Dr. David Bourne (Australian Institute of Marine Science)
Annegret de Baey-Diepolder
Venture Partner, Seventure Partners, München
Annegret de Baey-Diepolder
Annegret de Baey-Diepolder is a Venture Partner at Seventure Partners SA. Formerly she was co-founder and CEO of RNA-based immunotherapeutics company Rigontec GmbH, now Merck & Co., Inc..
As a life science industry consultant and former partner at private equity and venture capital companies TVM Capital and Gimv NV, she brings more than 15 years of experience in the life science and venture capital sector.
Program Manager, Digital Health Accelerator & Community Building, Berlin Health Innovation, BIH, Berlin
Bio coming soon.
Acting Director, BIH Biomedical Innovation Academy, Berlin
Duska Dragun has been a full professor at the Charité since 2008 and works as Managing Director at the Department of Nephrology and Intensive Care Medicine at Campus Virchow-Klinikum. She studied medicine in Zagreb, Croatia, until 1993 and received her doctoral degree from Humboldt University in Berlin. She has been awarded many national and international awards and fellowships. She is a member of the Editorial Board of “Transplantation” and has published over 100 peer-reviewed papers including publications in “Cell” and “The New England Journal of Medicine”.
Jorge Juan Fernandez Garcia
Director of Innovation, EIT Health, Barcelona
Jorge Juan Fernandez Garcia
Bio coming soon.
Visiting Professor, Berlin Institute of Health, Berlin
Bio coming soon.
UnternehmerTUM, Innovation Consultant, Munich
Sarah-Madeleine Gabler is an Innovation Consultant focused on Med Tech and Innovation in the Pharma Industry sector. She is experienced in Project-& Innovationsmanagement, as well as in Business modeling and Start-up Scouting.
Head, Innovation Center, Merck Group, Frankfurt am Main
Michael Gamber is the Head of the Merck Innovation Center and worked on the development of the concept of the Innovation Center for more than three years in his role as Merck Inhouse Consultant before taking over the lead of the Innovation Center in 2015.
With an academic background in business administration, information management and business education he joined the Inhouse Consulting department of Merck in 2010. In this role Michael worked on different projects dealing with innovation management, strategy and business process management. Prior to that Michael held different international consulting roles at PA Consulting Group, Capco and PricewaterhouseCoopers. Michael received his diploma from the University of Mannheim in 2005.
Group Leader, German Center for Neurodegenerative Diseases, Berlin
Prof. Craig Garner received his doctoral degree in Biochemistry at Purdue University and did his postdoctoral studies at the Friedrich Miescher Institute in Basel, CH and was a junior group leader at the Center for Molecular Neurobiology in Hamburg. His most recent faculty appointment was at Stanford University as Professor in the Department of Psychiatry and Behavioral Science, where he co-directed the Stanford Down syndrome Center. In 2014, he became a Scientist/co-Speaker of the DZNE-Berlin: German Center for Neurodegenerative diseases and Professor at the Charité –Universitätsmedizin Berlin. In 2015, he co-founded SPARK-Berlin to help educate academic scholars about translation and entrepreneurship. He has also founded three biotech companies, “Balance Therapeutics”, “Stealth Biosciences” and Navan Technologies. He maintains an active basic research program focused on the molecular and physiological mechanisms of synapse assembly and function in health and neurodegenerative diseases.
John E. Greenwood AM
Medical Director, Adult Burn Service, Royal Adelaide Hospital, Adelaide
John E. Greenwood AM
John Greenwood AM is an English-trained plastic surgeon who graduated from the University of Manchester in 1989 and now working full-time in burn care as the Medical Director of the Adult Burn Centre of the Royal Adelaide Hospital in Adelaide, South Australia. He has been developing skin replacement products, utilising the NovoSorb biodegradable polyurethane platform, since 2004. He was appointed Member of the Order of Australia (AM) following his work leading Australia’s only Burns Assessment Team after the carnage of the 2002 Bali Bombings which killed 202 civilians. He was the 2016 South Australian Australian of the Year.
Partner, DLT Capital, Munich
Jasmin Güngör is partner at DLT Capital, a consulting company that specializes on ICO and blockchain advisory services, investor relations and research. She first got to know Bitcoin in 2011 and has been watching the crypto market ever since, following all technical innovations with much interest. Next to her adivsory position at DLT Capital, she also speaks at conferences and meetups. Jasmin studied International Business Sciences at the University of Innsbruck and the Bogazici University in Istanbul. Between 2014 and 2018 she has been impact investing manager at Don Bosco. Other stations in her life have been: the Business Agency of Lower Austria, the University of Vienna as well as lecturing activities on behalf of the Vienna Stock Exchange.
Professor, Charité - Universitätsmedizin Berlin & Berlin Institute of Health, Berlin
Apr. 2018 – present: Full Professor (W3), Charit´e Medical School Berlin & Berlin Institute of Health.
Nov. 2011 – Mar. 2018: Max Planck research group leader (topic free), Max Planck Institute of Experimental Medicine.
Apr. 2005 – Jul. 2011: Postdoctoral & Associate researcher, Hebrew University of Jerusalem, Racah Institute of Physics and Interdisciplinary Center for Neural Computation.
Nov. 2006 – Feb. 2007: Visiting researcher, Harvard University, Center for Brain Science.
Mar. 2004 – Mar. 2005: DFG project leader, Humboldt University Berlin, Institute for Theoretical Biology.
Mar. 2004 – Jul. 2004: Visiting researcher, Hebrew University of Jerusalem, Interdisciplinary Center for Neural Computation.
Jul. 2003 – Feb. 2004: Postdoctoral researcher, Humboldt University Berlin, Institute for Theoretical Biology.
Academic education & Degrees
Dec. 2002: “Doctor rer. nat.” ( PhD) (University of Freiburg, Germany).
Oct. 1999 – Dec. 2002: University of Freiburg – PhD program in Neuroscience.
Oct. 1999: “Vordiplom” ( BSc) in Psychology (University of Heidelberg, Germany).
Oct. 1997 – Sep. 1999: University of Heidelberg – Psychology, Statistics.
Dec. 1997: Master of Philosophy (University of Cambridge, UK).
Oct. 1996: – Sep. 1997 University of Cambridge – Masters program in Theoretical Physics.
Oct. 1995: “Vordiplom” ( BSc) in Physics (Free University Berlin, Germany).
Oct. 1993: – Sep. 1996 Free University Berlin – Physics, Computer Science, Mathematics.
May, 1993: “Abitur” ( A-Levels) (Berlin, Germany).
May, 1991: High School Diploma of Graduation (Phoenix, Arizona, USA).
PhD Thesis: Cooperative Dynamics in Neural Networks – Models and Analyses Based on Interacting Point Processes. Advisor: Prof. Dr. Aertsen, Institute of Biology III, University of Freiburg.
Masters Thesis: On Scalar Quantum Fields Interacting with a Moving Dielectric. Advisor: Prof. Dr. Eberlein, Cavendish Laboratory, University of Cambridge.
Peer reviewed funding & Awards (selected)
Feb. 2017 2016: AAAS Newcomb-Cleveland Prize for best Science publication of the year.
Nov. 2011 – Nov. 2018: Independent Max Planck Research Group (“Free Floater”).
Sep. 2014: German Science Foundation Grant (DFG, GU 605/3-1 “Scientific Symposium”).
Sep. 2010 – Nov. 2010: KITP & Rice Family Fund Award (Emerging Techniques in Neuroscience Program).
Jul. 2008 – Jul. 2011: German Science Foundation Grant (DFG, GU 605/2-1 “Forschungsstipendium”).
Nov. 2005 – Nov. 2007: Hans Jensen Named Fellowship, Minerva Foundation (Max Planck Society).
Mar. 2004 – Mar. 2005: German Science Foundation Grant (DFG, GU 605/1-1 “Eigene Stelle”).
Dec. 1993 – Feb. 2003: Undergraduate & PhD scholarships (German Academic Scholarship Foundation).
Chief Business Officer, Massachusetts Biotechnology Council, Cambridge, MA
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.
John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.
Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University.
Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding.
John currently sits on the Advisory Board of MTTC (the MA Technology Transfer Center).
John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.
Dietmar W. Hutmacher
QUT Chair in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane
Dietmar W. Hutmacher
Dietmar W Hutmacher is Distinguished Professor and Chair of Regenerative Medicine at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. He directs the ARC ITTC in Additive Biomanufacturing and QUT Centre in Regenerative Medicine. D/Prof Hutmacher has eminent track record in biomedical engineering, tissue engineering & regenerative medicine. D/Prof Hutmacher did build a research program that gained global recognition and his interdisciplinary network goes beyond current mainstream collaboration configurations. D/Prof Hutmacher’s international standing and impact on the field are illustrated by his publication record (more than 300 journal articles, 14 edited books, >50 book chapters and citation record in scopus >26.000 citations, h-index 80. He is one of very few academics in the field of regenerative medicine who has taken a research program from bench to bedside and commercialization.
Founder, eXXclaim Capital & EILSF, Los Altos, CA
Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula’s expertise consists of a unique combination of business, basic science and medical knowledge.
Recognizing the growing yet under-invested opportunity in Women’s Health, in 2013 Anula launched eXXclaim Capital, focused on catalyzing innovation, entrepreneurship and investment in this field and has already made several investments. In 2006 Anula co-founded the “Evolvence India Life Science Fund” (EILSF), to make investments in pharmaceutical, biotechnology, medical device and contract services companies based in India. EILSF has garnered three successful exits to date and India Life Science 11 has had its first close.
She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, in England. Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, Hyderabad and nVision, San Francisco. She was previously a board member of Health Care Global which was exited to Temasek, Lipomics which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.
Head of Industry Cooperations & Partnerships, Berlin Health Innovation, BIH, Berlin
Bio coming soon.
General Manager, Digital Health Services, Siemens Healthineers, Siemens Healthcare, Erlangen
Dr. Arthur Kaindl has been General Manager of Digital Health Services at Siemens Healthineers since December 2015. Dr. Kaindl previously worked as Chief Executive Officer for the Imaging Informatics Business at Siemens AG Healthcare Sector. He joined Siemens AG in 1995 after finishing his studies at the Friedrich-Alexander University in Erlangen-Nuremberg and a master’s degree in Ceramics Engineering from the New York State College at Alfred University. Since finishing his Ph.D. in Electrical Engineering in 2001 from Hannover University, Dr. Kaindl has held various management positions in the field of Magnetic Resonance.
Consultant, Dutch Blockchain Team, Deloitte, Den Haag
Anna Klapwijk is consultant in the Dutch Blockchain team of Deloitte. She has been educated as a Strategic Product Designer at the Technical University of Delft, where she specialized in Medesign as well as Entrepreneurship. After graduating on blockchain in healthcare at Deloitte, she started working there as a strategist in the blockchain team. She prefers to term ‘creative strategist’ and combines knowledge of technology, business and people to develop services and solutions and in the blockchain space. The focus areas she works on are healthcare, life sciences and supply chain. Anna is an adventurer, explorer and a bit of a rebel.
Investment Manager, High-Tech Gründerfonds, Bonn
Lena joined HTGF in 2016 as an Investment Manager in the Life Science Team, and is currently responsible for sourcing and the completion of new early-stage investments. In addition, she has four portfolio companies, active in the fields of medical technology, drug development, biotechnology and digital health. Before coming to HTGF, she worked as Postdoctoral Researcher at the University Hospital in Erlangen, and obtained her PhD in Immunology within a DFG-funded Fast-track PhD program at the Friedrich-Alexander University Erlangen-Nürnberg. The thesis resulted in several publications in renowned journals including The Journal for Experimental Medicine. Lena completed her Bachelor’s degree from the Georg-August University Göttingen, and also spent time studying abroad in Umeå (Sweden) and Singapore.
President & Vice-Chancellor, University of Surrey, Surrey
Professor Max Lu has been President and Vice-Chancellor of University of Surrey since April 2016. Previously he was Provost and Senior Vice-President at the University of Queensland, Australia. He has been appointed to the Prime Minister’s Council for Science and Technology, the Boards of UK Research and Innovation, National Physical Laboratory, Universities UK, and serves on the Leadership Council of the National Centre for Universities and Business. He is Deputy Lieutenant of County of Surrey. Professor Lu lectured at Nanyang Technological University from 1991 to 1994, and had held academic and leadership positions at the University of Queensland from 1994 to 2016, rising from senior lecturer to chair professor. He founded the Australian Research Council Centre of Excellence for Functional Nanomaterials and served as its inaugural director for 8 years. He was awarded the Australian Research Council (ARC) Federation Fellowship twice, respectively, in 2003 and 2008.
As a double Highly Cited Researcher in both Materials Science and Chemistry, he has published over 500 journal papers on nanomaterials (h=111 and over 50,000 citations @Scopus). He is co-inventor of more than 20 granted international patents. He has been honoured with numerous awards including Orica Award, RK Murphy Medal, Le Fevre Prize, ExxonMobil Award, China International Science and Technology Award, Japan Chemical Society Lecture Award, Chemeca Medal, and P.V. Danckwerts Lecture. He was also recently honoured with a Medal of the Order of Australia (Officer in the General Division) for his distinguished service to education and international research in the field of materials chemistry and nanotechnology, to engineering, and to Australia-China relations.
Professor Lu has served on many government committees and advisory boards including those under the Australian Prime Minister’s Science, Engineering and Innovation Council, ARC College of Experts, Australian Synchrotron, Stem Cells Australia. He is Fellow of Institution of Chemical Engineers, Royal Society of Chemistry, Australian Academy of Science, Australian Academy of Technological Sciences and Engineering, and World Academy of Science.
Partner, Cooley, Frankfurt
Michael J. McGrail's practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Mike is fluent in German, and a significant portion of his practice is devoted to international transactions.
Boston College Law School, JD, 2001, cum laude
Northeastern University, BA, 1993, magna cum laude
District of Columbia
German American Business Counsel
Marina Leonie Moskvina
Expert Personal Development & Coaching, Entrepreneurship & Tech Education, UnternehmerTUM, Munich
Marina Leonie Moskvina
Marina Leonie Moskvina works in the field of leadership and business coachings, personel development as well as Human Resources Consulting for over five years. She is also responsible for formats in the field of MedTech and Healthcare Innovation in corporation with hospitals in Munich. She also stays in close touch with the entrepreneurial scene and supports startups and accelerator programs as a HR mentor and consultant.
Dominik N. Müller
Head of Research Group, Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Berlin
Dominik N. Müller
Education / Training
1991: Free University of Berlin, Pharmacy
1996: Free University of Berlin, PhD, Pharmacy
2004: Charité, Berlin, Postdoctural thesis, Experimental medicine
Positions and Honors (chronological order)
1996 – 2000 Post-doc Research Assistant, Volhard Clinic, Berlin, Germany
2001 – 2004 Post-doc Research Assistant, Max-Delbrück-Center, Germany
2004 – 2010 Group Leader, Delbrück Fellow at Max-Delbrück-Center
2010 - 2012 Professor, Experimental Medicine, Friedrich-Alexander University, Nikolaus-Fiebiger Center, Erlangen, Germany
2010 - Group Leader, Experimental and Clinical Research Center at Max-Delbrück-Center
Honors and Activities
2000 Young investigator award of the German Hypertension Society
2001 Poster Prize of the German Nephrology Society
2002 New Investigator Award for European Fellows, Council for High Blood Pressure Research, American Heart Association
2002 Dieter-Klaus Förderpreis of the German Hypertension Society
2004 Editorial Board “Hypertension”
2006 ADUMED Forschungspreis
2007 Renin Academy Young Investigator Award
2009 Best basic science paper of 2008 – Hypertension
2013 APL professorship at Charité
2013 Co-Founder of Omeicos Therapeutics
2013 AHA HBPR committee Liaison, Coordinator, International Mentoring
2013 AHA HBPR Fall Conference Program on the Leadership Committee
2018 Associate Editor “Cardiovascular Research”
Dominik N. Müller (PhD) heads a translational group at the Experimental and Clinical Research Center & Max-Delbruck Ctr for Molecular Medicine in the Helmholtz Association. The group’s major research interests are the renin-angiotensin system, the immune system and how both systems cause hypertension-induced target-organ damage. Recent work has extended the concept analyzing how environmental factors such as a high salt affect the microbiome, immune cells, target organs, and autoimmunity.
Co-Founder & Managing Partner, Flying Health Incubator, Berlin
Dr. Markus Müschenich is a board certified pediatrician and holds a Master degree in Public Health. For more than 10 years he has been a board member of non-profit and private hospital groups He is founding and board member of the German Association for Internet Medicine and Venture Partner in the investment team of Peppermint Venture Partners.
Dr. Markus Müschenich is Managing Partner of the Flying Health Incubator which focuses on digital health startups developing Digital Biomarkers & Software-as-a-Drug solutions. Dr. Markus Müschenich is regarded as a specialist for digital medicine of the future.
Founder & CEO, Ada Health, Berlin
Daniel Nathrath is Co-Founder & Chief Executive Officer of Ada, an AI powered health guide that helps people understand their health and navigate to the next appropriate steps in their care.
As a serial entrepreneur in consumer technology, Daniel helped drive the shift of Ada from a purely doctor-facing tool to a global consumer app after seeing a huge need in the market. Ada has become one of the world’s fastest growing medical apps, supporting millions of individuals globally. Ada’s platform also supports clinicians, research institutions and health systems to improve patient outcomes and inform clinical decision making.
Daniel has lived and worked in Germany, Denmark, the UK and the USA as Founder, Managing Director and General Counsel at several internet startups. He also spent some years as a Consultant at the Boston Consulting Group. He trained as a lawyer in Germany and the USA, where he was a Fulbright Scholar, and earned his MBA from the University of Chicago.
Professor, Boston University & Executive Director & Principal Investigator, CARB-X Boston
Professor Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the Executive Director and Principal Investigator for CARB-X, a $455M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID) and the Wellcome Trust.
His research work focuses on the law and economics of antimicrobial resistance. He is an Associate Fellow at the Royal Institute of International Affairs (Chatham House). Professor Outterson was a founding member of the Antimicrobial Resistance Working Group at the CDC. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9 million project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative. Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.
He serves as the faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the American Association of Law Schools; former Editor-in-Chief of the Journal of Law, Medicine & Ethics; and the current President of the Board of the American Society of Law, Medicine & Ethics. Professor Outterson is an occasional author for the New England Journal of Medicine on health law topics and has published extensively in medical, legal and health policy journals. He practiced law for a dozen years, at McDermott, Will & Emery (Chicago) and Baker Donelson (Nashville).
Project Leader, pre-INCUBATION Entrepreneurial Network, UnternehmerTUM, Munich
Patrizia Pawelek is responsible for early stage start up ideas and teaming as a coach and trainer. She is focused on challenging Med Tech Innovations in all aspects of Entrepreneurship - to make them start up ready.
Managing Partner, Apollo Ventures, Hamburg
James Peyer, PhD is the Founder of Apollo Ventures, an impact-driven investment firm focused exclusively on creating medicines that can extend human lifespan and healthspan by treating the causes of the aging process. Apollo founds companies with scientists, invests in early stage therapeutics projects, and contributes time and expertise to all aspects of early stage biotech companies. Apollo has quickly become the largest investor focused on aging biology in the world.
Before Apollo, James worked with McKinsey & Company in New York, where he focused on building new biotech companies and developing cell therapies. James earned his doctorate in stem cell biology at University of Texas Southwestern in Dallas, where he was a National Science Foundation GRFP Fellow; he received his undergraduate degree in Immunology with Special Honors from the University of Chicago.
Co-Founder & Chief Operating Officer, Advise Connect Inspire, Cambridge, MA
Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. As Chief Operating Officer of ACI, she facilitates the successful US market entry of emerging companies from Europe and connects US-based startups with European investors and industry groups. Prior to joining the German Accelerator Life Sciences (GALS) and founding ACI in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Charité Foundation in Berlin, including the highly successful international healthcare industry conference, Charité Entrepreneurship Summit.
COO, BioWink, Berlin
Bio coming soon.
Co-Founder, Peppermint VenturePartners, Berlin
Joachim Rautter is a co-founder of Peppermint VenturePartners and Managing Partner of Peppermint Charité Biomedical Fund.
Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CryoTherapeutics GmbH and Labfolder GmbH.
Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies.
Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.
Walter L. Rust
Lawyer and Notary, MOCK Rechtsanwälte, Berlin & Attorney at Law, New York
Walter L. Rust
Main Practice: Corporate Law, special focus life science companies. For more than 30 years advice on formations of companies, venture financing up to IPO and trade sale. Advice on the drafting of articles of associations, shareholders’ agreements, participation agreements as well as license and distributor agreements
Sale of German companies to US investors.
Lecturer Berlin School of Economics and Law and Technical University, Berlin
Chairman of various Supervisory Boards
Partner of a mid-size partnership of lawyers and notaries in Berlin. Numerous clients in technology sector
Johannes Schneider Littfeld
Peppermint VenturePartners, Board Member, Berlin
Johannes Schneider Littfeld
Johannes Schneider Littfeld, MSc has been in endocrinology research at the Universities Giessen and Minneapolis, before he started his industry career at the management consulting firm Sudler&Hennessey. He than has been Managing Director and CEO with Ferring Biotechnik, Disetronic Medical Systems and Becton Dickinson. He served as Corporate Vice President at Otto Bock HealthCare and is Board Member of several international Healthcare companies.
Executive Director, Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, Berlin
Professor Michael Schuetz is a practicing orthopaedic surgeon and research leader in the field of trauma care and orthopaedic trauma research. Since April 2016 he holds the position of Chair for Trauma- and Reconstructive Surgery at the Humboldt & Free University of Berlin as well is the Director of the Centre for musculoskeletal Surgery at the Charité Hospital in Berlin.
From 2004 until 2016 Michael Schuetz was the Chair of Trauma at the Queensland University of Technology (QUT) as well as Director of Trauma at the Princess Alexandra Hospital and remains Adjunct Professor at QUT.
Professor Schuetz’s research interests lie in the fields of orthopaedic trauma surgery, trauma system management, fracture healing, regenerative medicine and implant development. He has published more then 200 peer-reviewed publications in high impact international journals including The lancet, Critical Care, Acta biomaterialia, Biomaterials and Science Translational Medicine. Michael has attracted over $8.5 million in funding to support his research from national and international granting organizations, including four Australian Research Council (ARC) Linkage Project Grants, one ARC Discovery Grant, one National Health and Medical Research Council (NHMRC) Development Grant and one National and International Research Alliances Program Grant from the Queensland Government.
He has also established longstanding strategic partnerships with key players in the orthopaedic device industry, which have yielded over $1.5 million in funding for his research program.
Professor Schuetz is a leader in advancing clinical practice in traumatology. He served as Chairman of the Asia Pacific Working Group on Implant Design Modifications form 2006-2011, focusing on the development of world first orthopaedic implants designed specifically for the anatomical characteristics of Asia Pacific populations. Prof Schuetz was a core member of the Queensland Trauma Plan and inaugural chair of the State-wide Clinical Network for Trauma in Queensland from 2007-2010. He served as Chair of the AO Research Foundation Institute Advisory Committee (Davos, Switzerland) from 2011 – 2016, and was member of the Australian Orthopaedic Association Strategic Research Board, Board Member of the Australian Orthopaedic Association Trauma Association and member of the Australian Trauma Committee of the Royal Australian College of Surgeons. He has also advised the Australian Government as member of the Protocol Advisory Sub-Committee, and as member of the Specialist Orthopaedic Clinical Advisory Group, both reporting to the Department of Health and Ageing.
In 2014 Michael received the Research Award of the Australian Orthopaedic Association (AOA).
More recently became Chairman of the AO Incubator Board / Zuerich CH - fostering “Proof of Concept” projects in the field of orthoapedic trauma with an annual budget of 5mill CHF.
Founder, mHealth, Israel
Levi Shapiro is the Founder of mHealth Israel, a non profit supporting Israel’s digital health startup community, with more than 4,000 members. mHealth Israel hosts Israel’s largest digital health conference, September 14th, with more than 700 health tech innovators. Levi is also an Adjunct Professor at IDC Herzliya, in the Adelson School of Entrepreneurship. He writes about healthcare and technology in the Jerusalem Post and advises several prominent global medtech and biotech companies.
During a career spanning more than two decades, including seven years in Beijing and Tokyo, Mr. Shapiro launched new business units (IBM), new products and services (Toyota) and a variety of technology startups (Two Minute Television, Snack Mobile, etc). He is an investor and Board Member in several Israeli connected health startups and formerly a General Partner in the Israel-based venture capital firm, Veritas. Mr. Shapiro holds degrees from Tulane (BA), Cornell (Asian Studies) and MIT (MBA).
Head, T3 - Technion Technology Transfer, Haifa
Benjamin Soffer joined the Technion as head of T3 - Technion Technology Transfer office in 2005. As part of his duties at T3, Mr. Soffer is responsible for the establishment of startup companies and the commercialization of technologies arising from the Technion research. His Experience spans over 25 years in the areas of investment, industry and government in Israel, Europe, and the United States. In addition, Mr. Soffer serves as CEO of AMIT, a Technion Incubator for biomedical innovation; CEO of the Technion DRIVE Accelerator, and Chairman of the ITTN – The Israeli Technology Transfer Organization. In addition Mr. Soffer serves on the boards of directors of numerous high growth companies. Prior to his position at the Technion, Mr. Soffer served as managing director of TopNotch Capital - and was as an investment advisor at Highbridge Capital. Between 1999 and 2003 he served as Israel's Economic attaché in Boston. There, Mr. Soffer was responsible for enhancing economic and business relations between Israel and the US Northeast region through private equity investments, joint ventures and trade. Prior to his tenure in Boston, Mr. Soffer served as special advisor to Dr. Orna Berry, Israel's chief scientist at the Ministry of Industry and Trade (currently known as Israel Innovation Authority) , where played a pivotal role in the initiation and implementation of innovative R&D programs. A certified lawyer in Israel and in the state of New York, Mr. Soffer has interned at Israel's Supreme Court and studied law at Tel Aviv University and at Ludwig Maximilian University in Munich. Additionally, he studied economics and business administration at Bar - Ilan University.
Co-Founder, Parity Technologies, London
Bio coming soon.
Ellen 't Hoen
Director, Medicines Law & Policy and Global Health Unit University Medical Centre Groningen, The Netherlands
Ellen 't Hoen
Ellen ‘t Hoen is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies. She works as an independent consultant in medicines law and policy for a number of international organisations and governments and is a researcher at the Global Health Unit of the University Medical Center Groningen, The Netherlands.
From 1999 until 2009 she was the director of policy for Médecins sans Frontières’ Campaign for Access to Essential Medicines. In 2009 she joined UNITAID to set up the Medicines Patent Pool (MPP), an initiative that negotiates patent licenses to ensure access to affordable generic medicines. She was the MPP’s first executive director until 2012.
She is a member of the Lancet Commission on Essential Medicines Policies, the Advisory Board of Universities Allied for Essential Medicines (UAEM) and the Editorial Board of the Journal of Public Health Policy.
In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property.
She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her latest book “Private Patents and Public Health: Changing intellectual property rules for public health.”
Evert Jan van Lente
Director EU-Affairs, AOK-Bundesverband, Berlin
Evert Jan van Lente
Evert Jan van Lente is Director EU-Affairs of the AOK-Bundesverband, Germany. He is involved in developments in the health sector on European level, especially in pharmaceuticals, medical devices, e- and mHealth, etc. He is based in Brussels and Berlin. The AOK-Group is the leading statutory health insurance with 25 Million insured persons in all states of Germany.
Before working on EU level he was Director of the Care Management / Contracting Department of AOK-Federal Association, responsible for care management and prevention. He was a management consultant in the Netherlands, served as deputy director of a company specialized on IT-Services for health funds in Germany and headed the AOK contracting department of a regional AOK organization in Hannover.
He studied economics in Amsterdam (Netherlands) and Goettingen (Germany).
Mr. van Lente is since 20 years an international consultant for health financing and organization and is lecturer at the University Ulm and the Bonn- Rhein-Sieg University of Applied Science.
Anita Katharina Wagner
Associate Professor, Harvard Medical School & Harvard Pilgrim Health Care Institute, Cambridge MA
Anita Katharina Wagner
Anita Katharina Wagner is a clinical pharmacist, pharmacoepidemiologist, and health policy researcher. She leads research and training programs to help generate evidence for policy decisions on medicines in health systems. Her current research focuses on health system questions around cancer therapies. She serves as pharmacoepidemiologist in the FDA’s Sentinel Initiative, a national system that tracks the safety of pharmaceuticals in the United States; co-directs the Harvard Medical School Fellowship in Health Policy and Insurance Research and the Department of Population Medicine Center for Cancer Policy and Program Evaluation; and is a Fellow at the Harvard Medical School Center for Bioethics.
Dr. Wagner received a Master of Public Health degree in international health and Doctor of Public Health degree in epidemiology from the Harvard School of Public Health. She holds a doctorate in clinical pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences and a German master-equivalent degree in pharmacy.
For the full bio please visit: www.populationmedicine.org/awagner.
Director, SPARK Australia, University of Technology Sydney (UTS), Sydney, Australia
Professor Michael Wallach has over 30 years of experience in basic and applied molecular parasitology with a background in both academic and industrial science. He did his training at the University of Michigan (B Sc) and the Hebrew University of Jerusalem (PhD), which he completed in 1980. From 1980-1984 he did a post-doctoral fellowship at the Rockefeller University, New York, NY under Professor William Trager in the area of malaria vaccine development and in 1984 he took up the position as a lecturer in Parasitology at the Hebrew University, Jerusalem, Israel.
From 1991-1993 Professor Wallach spent a sabbatical and an additional year working at the Institute of Microbiology, University of Bern, Switzerland where he led a group that validated a novel vaccine for coccidiosis in chickens (a devastating intestinal parasitic disease). He then returned to Israel to commence a period of work in industry at the Veterinary Division of Teva Pharmaceuticals Ltd. to bring his vaccine to the market. He completed the development of the product and the vaccine was launched in several countries around the world in 2002.
As a result of the successful translation of his research in parasitology, Professor Wallach was appointed (Sept. 2002) as the Inaugural Director of the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology, Sydney, Australia. During the period of 2002-2008, the institute grew to over 60 scientists working on a variety of Veterinary and Human infectious diseases with the aim to come up with real solutions to some of the world’s most challenging health problems. Several successful translational projects were developed as a result of Professor Wallach’s work during that period, which under his mentorship, has continued until today.
In 2013, Prof. Wallach was appointed as the inaugural director of the SPARK Sydney program, which was established to emulate the SPARK program in translational medicine developed at the Stanford University School of Medicine, USA. In 2015, Professor Wallach played a key role in the establishment of a Global SPARK consortium, which was formally recognized by representatives of SPARK programs from around the world in Taipei, Taiwan. The goal is to greatly increase the translational outcomes from research by academic staff from all participating institutions. In 2017, SPARK Global members came together in Tokyo to discuss the way in which SPARK programs will work together as a consortium into the future, and the discussion will continue in Berlin at the Charité in 2018. Already the consortium has grown to include 54 prestigious institutions from 15 countries. Professor Wallach is a core member of the steering committee for this global initiative.
Investment Manager, High-Tech Gründerfonds, Bonn
Marco Winzer has been with High-Tech Gründerfonds since its foundation and has helped to establish the fund. The economics graduate has many years of experience in financing start-ups in the life sciences industry and has supported a number of start-ups all along the value chain of the ‘Venture Capital Model’ – from seed financing to successful exit. Before working for HTGF, the Partner acquired expertise in consulting start-ups and held various positions at the Business Innovation Center Kaiserslautern as well as the Technologie-Beteiligungsgesellschaft and development bank KfW.
H. E. Lynette Wood
Australian Ambassador to Germany, Berlin
H. E. Lynette Wood
In Canberra, Ms Wood was First Assistant Secretary, International Division with the Department of the Prime Minister and Cabinet (PM&C). She has served as Assistant Secretary, Middle East Branch and Executive Branch at the Department of Foreign Affairs and Trade (DFAT). Ms Wood has also served overseas with postings in Canada and Germany.
Ms Wood holds a Master of Arts (International Relations) from the Australian National University, a Graduate Diploma in Foreign Affairs and Trade from Monash University and a Bachelor of Arts (Honours) from the University of Sydney.
CFO & Member of the Executive Board, Berlin Institute of Health, Berlin
Rolf Zettl has over 25 years of management experience in the life science and research area. He was the founding managing director of the resource center of the German genome project and co-founder and CFO/CEO of biotech companies. He then moved to the Charité – University Medicine Berlin where he was head of corporate development. From 2008 he worked as managing director of the Helmholtz-Association of German research centers, the largest research organization in Germany, before he moved just recently to the Berlin Institute of Health as its CFO and member of the executive board. For his whole professional career, Rolf was involved in tech transfer, business development, and financing activities. He will built on this knowledge to establish an ecosystem for innovation at the Berlin Institute of Health. Rolf is a biologist by training and did his PhD at the Max Planck Institute for plant breeding research in Cologne, Germany.